๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for EGFR-Mutant Non-Small Cell Lung Cancer

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: ORIENT-31 regimen, SBRT Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965NA1 site๐Ÿ“ Guangzhou Guangzhou University of Traditional Chinese Medicine ยท Tests: Furmonertinib 320mg qod po, Furmonertinib 160mg qd po Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC NCT05997719n/a1 site๐Ÿ“ Guanzhou Sun Yat-sen University Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC NCT07837739n/a1 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: Adjuvant EGFR-TKI Therapy Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA NCT05334277Phase 226 sites๐Ÿ“ Changchun๐Ÿ“ Chengdu๐Ÿ“ Dongguan Sun Yat-sen University ยท Tests: Furmonertinib, Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage โ…ข EGFR-mutant Non-small Cell Lung Cancer NCT07323056Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Sacituzumab Tirumotecan and Limertinib Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site๐Ÿ“ Busan Pusan National University Hospital ยท Tests: Local Therapy (Surgery or Radiotherapy) Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC NCT06863506Phase 21 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: befotertinib Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer NCT07738172Phase 31 site๐Ÿ“ Taipei National Taiwan University Hospital ยท Tests: Primary Tumor Resection, Osimertinib CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease NCT05257967NA1 site๐Ÿ“ Vancouver British Columbia Cancer Agency ยท Tests: Lumbar puncture and Phlebotomy AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases NCT06604689n/a1 site๐Ÿ“ Shanghai Fudan University ยท Tests: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC NCT05536505Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Foshan Guangdong Association of Clinical Trials ยท Tests: Adjuvant treatment for MRD positivity Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC NCT07742332Phase 21 site๐Ÿ“ Shanghai Peng Zhang ยท Tests: Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790Phase 3204 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fullerton๐Ÿ“ La Jolla Bristol-Myers Squibb ยท Tests: Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer NCT07806604n/a2 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai Betta Pharmaceuticals Co., Ltd. ยท Tests: Icotinib, Routine Observational A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases NCT07143045n/a34 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Alpha Biopharma (Jiangsu) Co., Ltd. ยท Tests: zorifertinib MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer NCT04762199Phase 11 site๐Ÿ“ Atlanta Emory University ยท Tests: Flt3/MerTK Inhibitor MRX-2843, Osimertinib Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage โ…ก-โ…ขB EGFR Sensitive Mutant NSCLC NCT05987826Phase 21 site๐Ÿ“ Shanghai Shanghai Zhongshan Hospital ยท Tests: Furmonertinib Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC NCT05805631Phase 21 site๐Ÿ“ Taipei Taipei Veterans General Hospital, Taiwan ยท Tests: Pemetrexed Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment NCT06106802Phase 21 site๐Ÿ“ Seoul Sehhoon Park ยท Tests: Lazertinib, Tepotinib Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) NCT05642572Phase 2454 sites๐Ÿ“ Daphne๐Ÿ“ Fairhope๐Ÿ“ Mobile SWOG Cancer Research Network ยท Tests: Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers NCT04410796Phase 218 sites๐Ÿ“ Sacramento๐Ÿ“ San Francisco๐Ÿ“ Tampa Memorial Sloan Kettering Cancer Center ยท Tests: Osimertinib, Carboplatin, Pemetrexed A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC NCT07462377Phase 18 sites๐Ÿ“ Los Angeles๐Ÿ“ East Brunswick๐Ÿ“ Lake Success EpiBiologics ยท Tests: EPI-326 Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer NCT04780568Phase 11 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer NCT05284539Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW NCT06355609Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: sunvozertinib in combination with Anlotinib Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC๏ผˆARMOR2501๏ผ‰ NCT06924398Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Postoperative EGFR-TKI Therapy A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer NCT07699328Phase 1, Phase 229 sites๐Ÿ“ Bedford Park๐Ÿ“ Clayton๐Ÿ“ Toronto Voronoi, Inc ยท Tests: VRN110755 A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer NCT07535437Phase 1, Phase 27 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Ivonescimab, Dato-DXd, Osimertinib Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC NCT04324164n/a1 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: Third-generation EGFR-TKI, EGFR-TKI
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy